Hello and Welcome to Patientsville.com, Your Source for all ELITEK information. We are dedicated to provide You with ELITEK safety information. Learn about ELITEK serious adverse events reported to Food and Drug Administration (FDA).
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ELITEK Safety Reports
Total ELITEK reports: 5.ELITEK FDA safety alerts: No.
Reported deaths: 3 Reported hospitalizations: 1.
Take ELITEK Side Effects Survey or Share Your ELITEK Story. Read More Here.
Health Professional from UNITED STATES reported ELITEK problem on Feb 15, 2007. Male patient, weighting 218.5 lb, was diagnosed with tumour lysis syndrome and was treated with ELITEK. After drug was administered, patient experienced the following problems/side effects: hyperbilirubinaemia, renal failure acute, septic shock. ELITEK dosage: unknown. During the same period patient was treated with IDARUBICIN, CYTARABINE, NEXIUM, SYNTHROID, ZANAFLEX, ELAVIL, NEURONTIN. Patient recovered.
ELITEK problem was reported by a Health Professional from UNITED STATES on Feb 15, 2007. Male patient, weighting 218.5 lb, was diagnosed with tumour lysis syndrome and was treated with ELITEK. After drug was administered, patient experienced the following problems/side effects: hyperbilirubinaemia, renal failure acute, septic shock. ELITEK dosage: unknown. During the same period patient was treated with IDARUBICIN, CYTARABINE, NEXIUM, SYNTHROID, ZANAFLEX, ELAVIL, NEURONTIN. Patient recovered.
Physician from UNITED STATES reported ELITEK problem on Feb 26, 2007. Male patient, weighting 218.5 lb, was diagnosed with tumour lysis syndrome and was treated with ELITEK. After drug was administered, patient experienced the following problems/side effects: hyperbilirubinaemia, septic shock. ELITEK dosage: unknown. During the same period patient was treated with IDARUBICIN, CYTARABINE, NEXIUM, SYNTHROID, ZANAFLEX, ELAVIL, NEURONTIN. Patient died on 02/20/2007.
ELITEK problem was reported by a Pharmacist from UNITED STATES on Mar 30, 2007. Male patient, weighting 6.50 lb, was diagnosed with hyperuricaemia and was treated with ELITEK. After drug was administered, patient experienced the following problems/side effects: bradycardia, cardiopulmonary failure, electrolyte imbalance, fluid overload, hyperkalaemia, metabolic abnormality management, oliguria. ELITEK dosage: 0.1 MG/KG REPEATED 12 HOURS LATER. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient died.
Physician from UNITED KINGDOM reported ELITEK problem on Apr 27, 2007. Female patient was diagnosed with juvenile chronic myelomonocytic leukaemia and was treated with ELITEK. After drug was administered, patient experienced the following problems/side effects: blood potassium increased, blood uric acid increased, tumour lysis syndrome. ELITEK dosage: 50 ML. Patient died.